Field Trip Psychedelics Inc. Launches Field Trip Basecamp, a therapeutic program designed for combat veterans, first responders and healthcare workers


Ryan Allway

July 2nd, 2020

Psychedelics, Top News


New program offers psychedelic-assisted psychotherapy that enables ‘frontliners’ and others in high-pressure occupations to “return, reset and relaunch” 

TORONTO , July 2, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced the launch of Field Trip Basecamp, a program focused on serving individuals suffering from debilitating mental health issues as a result of high-pressure occupations. The immediate focus of the new program will be on “frontliners,” including combat veterans, first responders, emergency room doctors and other professionals regularly exposed to traumatic experiences while on the job.

Veterans and first-responders experience disproportionately high levels of trauma and stressor-related mental health conditions like post-traumatic stress disorder (PTSD), depression, anxiety and substance abuse and dependency. Field Trip’s Basecamp therapy program offers a personalized, behavior-focused approach with the goal of “return, reset and relaunch,” allowing frontliners to reconnect with their families, rediscover their sense of purpose and reengage with life on their terms. Utilizing the dissociative psychedelic ketamine, participants will receive a unique form of enhanced psychotherapy that helps break old and harmful thought patterns, and maximizes the window of neuroplasticity created through the ketamine treatments.

“Trauma has a way of robbing life of meaning. Home doesn’t feel like home and work doesn’t seem important. Veterans have long dealt with the lasting effects of PTSD and, throughout the COVID-19 crisis, more and more of our frontline healthcare workers are suffering similar effects,” said Ronan Levy , Executive Chairman of Field Trip Psychedelics. “The long-lasting trauma frontliners face is often treated with pharmaceuticals that fail to address the underlying cause of mental illness. We believe psychedelics and psychedelic-assisted psychotherapy can be the solution to reconnect frontliners with themselves and provide a new lease on life.”

At launch, Field Trip Basecamp will be available at the Company’s clinic located in Toronto and will be available in clinics opening in New York and Los Angeles later this summer. Field Trip is also partnering with veteran service organizations, first-responder associations and charities to reach potential participants and assist with treatment and travel costs.

“As a former Navy SEAL, I have watched teammates suffer from PTSD, depression, and multiple traumatic brain injuries. I have seen how existing pharmaceuticals like SSRI’s can affect the minds of high-performance individuals,” said Adam Wright , Director of Field Trip Basecamp. “Unfortunately, these medications can take at least six weeks to kick in, have terrible side effects and the treatment response is often highly variable. With Field Trip Basecamp, our treatment protocol is far more integrated, leveraging the psychedelic and neuroplasticity-enhancing effects of ketamine to support the custom-developed psychotherapy protocols that our team of psychiatrists, physicians, psychologists and psychotherapists have developed specifically for people in high-intensity professions.”

People interested in learning more, or those interested in being screened to participate in the Basecamp program, can find information at http://fieldtripbasecamp.com.

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America , and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading